CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE         Parliamentary submission
DATE               2014-03-26
TOPICS             Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs
April 6, 2017
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

POLICY TYPE
Policy document

DATE
2015-05-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE         2018-12-04
TOPICS       Pharmaceuticals, prescribing, cannabis, drugs
             Population health, health equity, public health

Documents
Health Canada consultation on regulatory amendments regarding tramadol

https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE       Response to consultation
DATE             2018-07-18
TOPICS           Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/link/policy13932

POLICY TYPE  Policy endorsement

DATE  2018-10-31

TOPICS  Population health, health equity, public health

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE  Response to consultation
DATE  2014-07-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE Response to consultation
DATE 2014-03-17
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

Statement to the House of Commons Committee on Health addressing the CMA Policybase - Canadian Medical Association
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE  Parliamentary submission
DATE  2016-10-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Opening Statement

House of Commons
Standing Committee on Health

Dr. Jeff Blackmer
Vice-President, Medical Professionals
Canadian Medical Association
Ottawa
October 18, 2016

Check against delivery

We must learn from health care models and policies that have had success on a regional scale and have proven solutions for similar populations in the United States, Australia, and other countries.
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE Policy endorsement

DATE 2018-08-30

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 16, 2018

Dear Premier Ford and Minister Elliott:

We, as Canadian emergency physicians, medical students and residents, strongly urge you to support the establishment of life-saving supervised consumption and overdose prevention sites (SC/OPS) and overdose prevention centres (OPC) in your jurisdiction. We, as emergency physicians, medical students and residents are trained to save and improve lives every day in our emergency rooms. Our colleagues worldwide use SC/OPS and OPC on an ongoing basis to save lives and prevent further harm to individuals who are addicted to illicit substances, from opioid users to cocaine, cannabis and other drug users. It is heartbreaking to see our patients enter our emergency rooms after drug use and often die or experience life-long harm.

In the face of the current opioid epidemic, the call for support and funding for such sites is urgent. Our patients are telling us that a supervised consumption site (SC) would be one step closer to a healthier life, while an overdose prevention centre (OPC) could save their life. As emergency physicians, we often consider our patients as our friends, we often become attached to them. Our patients are not destroying their lives, they are doing everything they can to survive, to give their children a better life. Our communities need support to save lives.

We urge you to support this proposal so that we can collectively help suffering individuals and save lives in our emergency rooms.

Sincerely,

[Signatures]

[Names]

Policy Type: Policy endorsement

Date: 2018-08-30

Topics: Pharmaceuticals, prescribing, cannabis, drugs

Documents: Tamper Resistance under the Controlled Drugs and Substances Act

CMA Policybase - Canadian Medical Association
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE  Response to consultation
DATE  2014-08-26
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents